Samir Mody
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Samir Mody has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Aarti A. Patel
Janssen Scientific Affairs, LLC, Titusville, USA
1 shared publication - Andrew F. Shorr
Washington Hospital Center, Washington, DC 20010, USA
1 shared publication - Andrew M Ramsey
EviMed Research Group, LLC, Goshen, MA, USA
1 shared publication - Brian Macomson
Janssen Scientific Affairs, LLC, Raritan, NJ, USA
1 shared publication - Duygu Bozkaya
Boston Health Economics, Inc, Waltham, MA, USA
1 shared publication - Gary M. Owens
President, Gary Owens Associates, Ocean View, DE.
1 shared publication
Latest Publications
- Open Access
- 28 July 2014
- Published by Springer Nature in BMC Health Services Research
- Vol. 14 (1) , 329
Anticoagulant use for the prevention of stroke in patients with atrial fibrillation: findings from a multi-payer analysis
Oral anticoagulation is recommended for stroke prevention in intermediate/high stroke risk atrial fibrillation (AF) patients. The objective of this study was to demonstrate the usefulness of analytic software tools for descriptive analyses of disease management in atrial AF; a secondary objective is to demonstrate patterns of potential anticoagulant undertreatment in AF.
- 28 July 2014
- Published by Springer Nature in BMC Health Services Research
- Vol. 14 (1) , 329
Open AccessAnticoagulant use for the prevention of stroke in patients with atrial fibrillation: findings from a multi-payer analysis
Oral anticoagulation is recommended for stroke prevention in intermediate/high stroke risk atrial fibrillation (AF) patients. The objective of this study was to demonstrate the usefulness of analytic software tools for descriptive analyses of disease management in atrial AF; a secondary objective is to demonstrate patterns of potential anticoagulant undertreatment in AF.
- Open Access
- 26 August 2010
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 10 (1) , 45
Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review
Pneumonia, and particularly nosocomial (NP) and ventilator-associated pneumonias (VAP), results in high morbidity and costs. NPs in particular are likely to be caused by Pseudomonas aeruginosa (PA), ~20% of which in observational studies are resistant to imipenem. We sought to identify the burden of PA imipenem resistance in pneumonia.
- 26 August 2010
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 10 (1) , 45
Open AccessImipenem resistance of Pseudomonas in pneumonia: a systematic literature review
Pneumonia, and particularly nosocomial (NP) and ventilator-associated pneumonias (VAP), results in high morbidity and costs. NPs in particular are likely to be caused by Pseudomonas aeruginosa (PA), ~20% of which in observational studies are resistant to imipenem. We sought to identify the burden of PA imipenem resistance in pneumonia.